News | October 30, 2009

PET Pinpoints Inflammation in Brains of Schizophrenics, Migraines

October 30, 2009 - By using positron emission tomography (PET) researchers were to able to identify neuroinflammation, which is marked by activated microglia cells (brain cells that are responsive to injury or infection of brain tissue) in patients with schizophrenia and in animal models with migraines. This information could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of The Journal of Nuclear Medicine.

Although neuroinflammation has been shown to play a major role in many neurodegenerative disorders—such as multiple sclerosis, Parkinson's disease and Alzheimer's disease—only limited data exists about the role of neuroinflammation in schizophrenia and migraines. The two studies in The Journal of Nuclear Medicine are the first to identify neuroinflammation in specific regions of the brain—a development which could be used to effectively evaluate the treatment response to anti-inflammatory drugs and become transformative for diagnosis and care.

"This study shows that molecular imaging can play an important role in better understanding the processes involving psychiatric and other neurological disorders," said Janine Doorduin, M.Sc., a researcher at the University Medical Center Groningen in the Netherlands and lead author of "Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study." Doorduin added: "Without molecular imaging, the only way to look at inflammation in the brain, as well as other molecular processes, would be to use post-mortem brains."

Not much is known about the cause of schizophrenia—a chronic and disabling brain disease characterized by psychotic episodes of delusions and hallucinations. Previously, evidence from post-mortem studies suggested the presence of activated microglia cells in the brain. However, the results of those studies were inconsistent. Using PET imaging to noninvasively image the living brains of schizophrenic patients, researchers in the Netherlands were able to pinpoint the neuroinflammation to an exact location in the brain, called the hippocampus. Now, researchers can target the hippocampus for further study and evaluate therapeutic treatments that could improve the quality of life for patients living with schizophrenia.

Likewise, PET imaging is also useful for identifying neuroinflammation associated with migraines. In the article, "11C-PK11195 PET for the In Vivo Evaluation of Neuroinflammation in the Rat Brain After Cortical Spreading Depression," researchers in Japan were the first to noninvasively visualize neuroinflammation in an animal model of migraine using a PET technique. Neuroinflammation is thought to be a key factor in the generation of pain sensation in migraine headaches. Observations from the study suggest that an inflammatory process may be involved in the pathologic state of migraines and that PET is a useful tool for evaluating the neurogenic inflammation in vivo.

"For physicians and patients, it is important to develop an objective method for the diagnosis of migraines and monitor therapeutic efficacy," said Yi-Long Cui, Ph.D., a researcher at the RIKEN Center for Molecular Imaging Science in Kobe, Japan, and lead author of the study. "The present study will bring about these possibilities to us since the PET probe used in the paper has already been applied to patients in other diseases."

Co-authors of "11C-PK11195 PET for the In Vivo Evaluation of Neuroinflammation in the Rat Brain After Cortical Spreading Depression" include Yilong Cui, Yosky Kataoka, Yasuhisa Tamura, Cellular Function Imaging, RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan; Tadayuki Takashima, Yasuhiro Wada, Yasuyoshi Watanabe, Molecular Probe Dynamics, RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan; Misato Takashima-Hirano, Hisashi Doi, Molecular Imaging Labeling Chemistry, RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan; and Miho Shukuri, Hirotaka Onoe, Functional Probe Research Laboratories, RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan.

Co-authors of "Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study" include: Janine Doorduin, Erik F.J. de Vries, Antoon T.M. Willemsen, Rudi A. Dierckx, Hans C. Klein, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Jan Cees de Groot, Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and Hans C. Klein, University Center of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

For more information: jnm.snmjournals.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init